GNC-038 and GNC-039 (for “guidance, navigation and control”) of Bailey Pharmaceuticals and its subsidiary Systimmune, employ a novel octavalent format to engage and activate T-cells by binding CD3 and 4-1BB, while simultaneously also inhibiting PD-L1 on tumor cells and binding a TAA, namely CD19 and EGFRvIII on r/r NHL and various solid tumors, respectively (NCT04606433, NCT04794972). The gene discussed is CD274; the disease is neoplasm.